Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics
Mel Snyder, Healthcare Commercialization and Strategy Advisor at ProClinica Inc., shared a post on LinkedIn:
“Now, more than 5000 American children with sickle cell disease can access a genetic cure for a disease that causes pain, organ damage, loss of school days, ans limited participation in sports and other childhood activities.
Possibly more important: The FDA’s action on Casgevy/Sickle-Cell Disease suggests a more liberal view of extending to pediatric patients other genetic cures until now reserved for adults.
Since the vast majority of genetic diseases first appear in infants, this FDA action may encourage more investment in public and private biopharmas working on agents for other genetic diseases first seen in childhood.”
Stay updated with Hemostasis Today.
-
Sep 14, 2026, 11:16Zahra Ghasemi: Breaking the Freezer Barrier in Plasma Transfusion
-
Sep 14, 2026, 09:44Mohammad Salar Amoli: Thrombin The Master Regulator of Coagulation
-
Sep 14, 2026, 09:23Claire Harrison: HemaSphere Introduces New Patient Editor Role
-
Sep 14, 2026, 09:13Eirini Zorba: Plasmapheresis in Focus Understanding Its Role in Patient Care
-
Sep 14, 2026, 08:55Abdulrahman Al-Mashdali։ Immune Checkpoint Inhibitor Associated HLH
-
Sep 14, 2026, 07:54Islam Sadek: SOHO2026 Highlights Advances in Hematologic Malignancies
-
Sep 14, 2026, 07:45Flora Peyvandi: Building a More Equitable Future for Hemophilia Care
-
Sep 14, 2026, 07:37Joseph Pierre Aboumsallem: ET Treatment Enters a New Chapter
-
Sep 14, 2026, 07:29Eric Topol: Will AI Replace Clinicians?